Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy
and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and
suboptimal PIFR.
Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy
and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and
suboptimal PIFR.
Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution
Completed
Mylan Pharmaceuticals
Phase 1
2021-09-23
Single-Dose Fasting Bioavailability Study of Revefenacin Inhalation Solution, 175 mcg/3 mL in
24 Healthy Chinese Adult Male and Female Volunteers. This study will evaluate the safety and
tolerability of Revefenacin Inhalation Solution in the Chinese population. For the
determination of the pharmacokinetic disposition of the formulations, The bioavailability of
Revefenacin Inhalation Solution, 175 mcg/3 mL will be assessed through various
pharmacokinetic parameters derived from the plasma concentration-time curves of revefenacin
and its active metabolite, THRX-195518.
Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution
Completed
Mylan Inc.
Phase 1
2021-09-23
Single-Dose Fasting Bioavailability Study of Revefenacin Inhalation Solution, 175 mcg/3 mL in
24 Healthy Chinese Adult Male and Female Volunteers. This study will evaluate the safety and
tolerability of Revefenacin Inhalation Solution in the Chinese population. For the
determination of the pharmacokinetic disposition of the formulations, The bioavailability of
Revefenacin Inhalation Solution, 175 mcg/3 mL will be assessed through various
pharmacokinetic parameters derived from the plasma concentration-time curves of revefenacin
and its active metabolite, THRX-195518.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
